title: Summit’s dual-acting drug scores lung cancer win
source: Yahoo
date: 2025-10-20
url: https://finnhub.io/api/news?id=aeaad502b8688f719dd82dcca1201823a07459fe4b7561629036574b7439c6a7
A closely watched trial in Chinese patients is raising hope that ivonescimab will outperform Keytruda in a large global study that could reshape first-line treatment regimens.
